ZRG Partners Life Sciences Hiring Index Shows Modest Gains in 4th Quarter
ZRG Partners, Inc. announces the results of its fourth quarter Global Life Sciences Hiring Index
ZRG Partners, Inc. announces the results of its fourth quarter Global Life Sciences Hiring Index. Q4 reflects an overall gain in hiring, with Pharma activity over the long term reaching an all-time index high. Meanwhile R&D hiring took a hit dropping 15% from the previous quarter. The Asia Pacific Region saw significant hiring in Q4, more than 25%, with most being attributed to the Sales and Marketing function.
ZRG Managing Director David Fortier commented, “The results of this latest index correlate with the broader economy – inconsistencies across regions, sectors, and functions along with the continuation of a longer term trend of slow, steady, but uneven growth. The positive to take from these numbers is some robust hiring in selected functions within pharmaceuticals and a return of hiring in the commercial function indicating expectations of growth for some companies.”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
